Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. (Q55474303)

12 July 2018

title

Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. (English)

1 reference

12 July 2018

1 reference

Huang Y

1

1 reference

12 July 2018

Hayes RL

2

1 reference

12 July 2018

Wertheim S

3

1 reference

12 July 2018

Arbit E

4

1 reference

12 July 2018

Scheff R

5

1 reference

12 July 2018

publication date

1 July 2001

1 reference

12 July 2018

Critical Reviews in Oncology Hematology

published in

1 reference

12 July 2018

volume

39

1 reference

12 July 2018

issue

1-2

1 reference

12 July 2018

page(s)

17-23

1 reference

12 July 2018

Primary central nervous system tumors: advances in knowledge and treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Cytolytic effects of autologous lymphokine-activated killer cells on organotypic multicellular spheroids of gliomas in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Effect of Local Administration of Lymphokine-activated Killer Cells and Interleukin-2 on Malignant Brain Tumor Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Immunotherapy with Stimulated Autologous Lymphocytes in a Case of a Juvenile Anaplastic Glioma*

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

1 reference

7 January 2021

Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900120-2

7 January 2021

10.1016/S1040-8428(01)00120-2

Identifiers

DOI

1 reference

12 July 2018

1 reference

12 July 2018